NCT06454578View on ClinicalTrials.gov

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Adebrelimab + Apatinib

"the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years"

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER